These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22870852)

  • 1. Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.
    Jagessar SA; Heijmans N; Oh L; Bauer J; Blezer EL; Laman JD; Migone TS; Devalaraja MN; 't Hart BA
    J Neuroimmune Pharmacol; 2012 Sep; 7(3):557-70. PubMed ID: 22870852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The different clinical effects of anti-BLyS, anti-APRIL and anti-CD20 antibodies point at a critical pathogenic role of γ-herpesvirus infected B cells in the marmoset EAE model.
    Anwar Jagessar S; Fagrouch Z; Heijmans N; Bauer J; Laman JD; Oh L; Migone T; Verschoor EJ; 't Hart BA
    J Neuroimmune Pharmacol; 2013 Jun; 8(3):727-38. PubMed ID: 23508625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant.
    Jagessar SA; Heijmans N; Blezer EL; Bauer J; Weissert R; 't Hart BA
    J Neuroinflammation; 2015 Sep; 12():169. PubMed ID: 26377397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late B cell depletion with a human anti-human CD20 IgG1κ monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosets.
    Kap YS; van Driel N; Blezer E; Parren PW; Bleeker WK; Laman JD; Craigen JL; 't Hart BA
    J Immunol; 2010 Oct; 185(7):3990-4003. PubMed ID: 20739677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell depletion abrogates T cell-mediated demyelination in an antibody-nondependent common marmoset experimental autoimmune encephalomyelitis model.
    Jagessar SA; Heijmans N; Bauer J; Blezer EL; Laman JD; Hellings N; 't Hart BA
    J Neuropathol Exp Neurol; 2012 Aug; 71(8):716-28. PubMed ID: 22805775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
    Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses.
    Huntington ND; Tomioka R; Clavarino C; Chow AM; Liñares D; Maña P; Rossjohn J; Cachero TG; Qian F; Kalled SL; Bernard CC; Reid HH
    Int Immunol; 2006 Oct; 18(10):1473-85. PubMed ID: 16914508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental Autoimmune Encephalomyelitis (EAE) Model of Cynomolgus Macaques Induced by Recombinant Human MOG1-125 (rhMOG1-125) Protein and MOG34-56 Peptide.
    Peng Z; Zhang L; Wang H; He X; Peng X; Zhang Q; Liu H; Rao J; Wang H; Wu J; Sun Y
    Protein Pept Lett; 2018 Feb; 24(12):1166-1178. PubMed ID: 29141529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of experimental autoimmune encephalomyelitis with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant in three non-human primate species.
    Haanstra KG; Jagessar SA; Bauchet AL; Doussau M; Fovet CM; Heijmans N; Hofman SO; van Lubeek-Veth J; Bajramovic JJ; Kap YS; Laman JD; Touin H; Watroba L; Bauer J; Lachapelle F; Serguera C; 't Hart BA
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1251-64. PubMed ID: 23821341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses.
    Boon L; Brok HP; Bauer J; Ortiz-Buijsse A; Schellekens MM; Ramdien-Murli S; Blezer E; van Meurs M; Ceuppens J; de Boer M; 't Hart BA; Laman JD
    J Immunol; 2001 Sep; 167(5):2942-9. PubMed ID: 11509643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice.
    Wilson NA; Bath NM; Verhoven BM; Ding X; Boldt BA; Sukhwal A; Zhong W; Panzer SE; Redfield RR
    Transplantation; 2019 Jul; 103(7):1372-1384. PubMed ID: 30830041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model.
    Bath NM; Ding X; Wilson NA; Verhoven BM; Boldt BA; Sukhwal A; Reese SR; Panzer SE; Djamali A; Redfield RR
    PLoS One; 2019; 14(2):e0211865. PubMed ID: 30735519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies.
    Shivakumar L; Ansell S
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):106-8. PubMed ID: 17026820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of early IL-17A neutralization on disease induction in a primate model of experimental autoimmune encephalomyelitis.
    Kap YS; Jagessar SA; van Driel N; Blezer E; Bauer J; van Meurs M; Smith P; Laman JD; 't Hart BA
    J Neuroimmune Pharmacol; 2011 Sep; 6(3):341-53. PubMed ID: 20700661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
    Dillon SR; Harder B; Lewis KB; Moore MD; Liu H; Bukowski TR; Hamacher NB; Lantry MM; Maurer M; Krejsa CM; Ellsworth JL; Pederson S; Elkon KB; Wener MH; Dall'Era M; Gross JA
    Arthritis Res Ther; 2010; 12(2):R48. PubMed ID: 20302641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting.
    Baert L; Manfroi B; Casez O; Sturm N; Huard B
    J Autoimmun; 2018 Dec; 95():179-190. PubMed ID: 30385081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD20+ B cell depletion alters T cell homing.
    Kap YS; van Driel N; Laman JD; Tak PP; 't Hart BA
    J Immunol; 2014 May; 192(9):4242-53. PubMed ID: 24696233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell depletion attenuates white and gray matter pathology in marmoset experimental autoimmune encephalomyelitis.
    Kap YS; Bauer J; Driel Nv; Bleeker WK; Parren PW; Kooi EJ; Geurts JJ; Laman JD; Craigen JL; Blezer E; 't Hart BA
    J Neuropathol Exp Neurol; 2011 Nov; 70(11):992-1005. PubMed ID: 22002426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticytokine therapy impacting on B cells in autoimmune diseases.
    Daridon C; Burmester GR; Dörner T
    Curr Opin Rheumatol; 2009 May; 21(3):205-10. PubMed ID: 19346949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.